

## Bio-Pharm Acquired by Torrent Pharma

### Torreya advised Bio-Pharm on Sale

Levittown, Pennsylvania, USA and Gujarat, India, January 19, 2018

Bio-Pharm, Inc., a high-growth CDMO, headquartered in Levittown, Pennsylvania, focused on manufacturing niche liquid and suppository generic pharmaceuticals, has been acquired by Torrent Pharmaceuticals Limited, a pharmaceutical company headquartered in Gujarat, India. The transaction value was not disclosed.



The Bio-Pharm acquisition is aligned with Torrent's strategy to increase its presence in the United States by providing a manufacturing and R&D presence, as well as being consistent with their strategy of dosage form diversification.

Torreya acted as exclusive financial advisor to Bio-Pharm on the sale. This transaction highlights Torreya's expertise in the generic pharmaceutical and represents our 11<sup>th</sup> completed generics transaction in the past year.

### **ABOUT BIO-PHARM, INCORPORATED**

For more information about Bio-Pharm, please see: [www.bio-pharminc.com](http://www.bio-pharminc.com)

### **ABOUT TORRENT PHARMACEUTICALS LIMITED**

For more information about Torrent Pharma, please see: [www.torrentpharma.com](http://www.torrentpharma.com)

### **Deal Press Release**

### **Torreya Contact**

#### **ALLEN LEFKOWITZ**

Managing Director | New York Office  
[allen.lefkowitz@torreya.com](mailto:allen.lefkowitz@torreya.com) | 212.257.5823 | [torreya.com](http://torreya.com)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.